A Phase Ib, Multicentre, Randomised, Double-blind, Placebo Controlled, 8 Week Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered BI 705564 in Patients With Systemic Lupus Erythematosus.
Latest Information Update: 04 Nov 2021
At a glance
- Drugs BI 705564 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Feb 2019 Planned End Date changed from 7 Nov 2019 to 7 Jan 2020.
- 04 Feb 2019 Planned primary completion date changed from 21 Oct 2019 to 21 Dec 2019.